FIELD: pharmacology.
SUBSTANCE: invention relates to the use of oreganol A as a diuretic (diuretic) agent.
EFFECT: invention makes it possible to increase the effectiveness of the therapeutic effect and exclude the occurrence of side effects.
9 cl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF PATULITRIN AS A DIURETIC | 2022 |
|
RU2807938C1 |
| USE OF QUERCETIN AS A DIURETIC, SALURETIC AND CREATININURETIC AGENT | 2022 |
|
RU2802833C1 |
| USE OF DIHYDROQUERCETIN AS A DIURETIC, SALURETIC AND CREATININURETIC AGENT | 2022 |
|
RU2802874C1 |
| USE OF HYPEROZIDE AS A DIURETIC, SALURETIC AND CREATININURETIC AGENT | 2022 |
|
RU2802832C1 |
| USE OF PINOSTROBIN AS DIURETIC AND CREATINURETIC AGENT | 2023 |
|
RU2816948C1 |
| USE OF PINOCEMBRIN AS DIURETIC AND CREATININURETIC AGENT | 2023 |
|
RU2822937C1 |
| USE OF GENISTEIN AS DIURETIC | 2023 |
|
RU2832826C1 |
| USE OF OREGANOL A WITH NEUROTROPIC ACTIVITY | 2022 |
|
RU2802871C1 |
| USE OF PATULYTHRIN AS AN ANTIDEPRESSANT | 2022 |
|
RU2802977C1 |
| DIURETIC | 2016 |
|
RU2619346C1 |
